BIOMM was created in 2001 as a split-off from Biobrás. By the end of the process, its intellectual property, know-how, the researchers who developed the technology and the executives who had made Biobrás the world’s fourth largest insulin producer had been transferred to BIOMM. Biominas aided the company in its business plan for a new biological drug production and sales unit in Brazil.
- Gauging of the size of the national market for the priority biological drugs;
- Analysis of the national business environment and implications for the company;
- Setting of financial feasibility parameters;
- Drafting of implementation strategy and action plan.
“Biominas’ participation was crucial for creating a realistic, balanced study. Their knowledge of the biopharmaceuticals market in Brazil, including regulatory issues, was crucial to the success of the study”.